Kodiak Sciences (KOD) Competitors $5.79 +0.15 (+2.66%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KOD vs. FATE, ADPT, RLAY, ARQT, ANIP, ARDX, BCAX, APLT, AVDL, and ZYMEShould you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Relay Therapeutics (RLAY), Arcutis Biotherapeutics (ARQT), ANI Pharmaceuticals (ANIP), Ardelyx (ARDX), Bicara Therapeutics (BCAX), Applied Therapeutics (APLT), Avadel Pharmaceuticals (AVDL), and Zymeworks (ZYME). These companies are all part of the "medical" sector. Kodiak Sciences vs. Fate Therapeutics Adaptive Biotechnologies Relay Therapeutics Arcutis Biotherapeutics ANI Pharmaceuticals Ardelyx Bicara Therapeutics Applied Therapeutics Avadel Pharmaceuticals Zymeworks Fate Therapeutics (NASDAQ:FATE) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings. Does the media refer more to FATE or KOD? In the previous week, Fate Therapeutics had 11 more articles in the media than Kodiak Sciences. MarketBeat recorded 22 mentions for Fate Therapeutics and 11 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.27 beat Fate Therapeutics' score of 0.24 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, FATE or KOD? Fate Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$63.53M3.98-$160.93M-$1.65-1.35Kodiak SciencesN/AN/A-$260.49M-$3.65-1.59 Is FATE or KOD more profitable? Kodiak Sciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% Kodiak Sciences N/A -84.52%-45.40% Which has more risk and volatility, FATE or KOD? Fate Therapeutics has a beta of 1.88, indicating that its stock price is 88% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Do analysts recommend FATE or KOD? Fate Therapeutics currently has a consensus target price of $6.75, suggesting a potential upside of 204.05%. Kodiak Sciences has a consensus target price of $3.50, suggesting a potential downside of 39.55%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Kodiak Sciences 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Do insiders & institutionals believe in FATE or KOD? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Comparatively, 45.3% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in FATE or KOD? Fate Therapeutics received 462 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 68.09% of users gave Fate Therapeutics an outperform vote while only 26.47% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48068.09% Underperform Votes22531.91% Kodiak SciencesOutperform Votes1826.47% Underperform Votes5073.53% SummaryFate Therapeutics beats Kodiak Sciences on 13 of the 17 factors compared between the two stocks. Ad Angel PublishingTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Get Kodiak Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOD vs. The Competition Export to ExcelMetricKodiak SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.80M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-1.5916.1687.8613.46Price / SalesN/A282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book1.644.436.946.30Net Income-$260.49M-$41.63M$119.12M$225.93M7 Day Performance9.25%-4.73%-1.84%-1.32%1 Month Performance57.77%-6.53%-3.65%0.60%1 Year Performance157.33%25.63%31.64%26.23% Kodiak Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KODKodiak Sciences2.983 of 5 stars$5.79+2.7%$3.50-39.6%+138.3%$296.80MN/A-1.5990FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradeNews CoverageADPTAdaptive Biotechnologies4.3927 of 5 stars$4.42-1.3%$6.50+47.1%-0.5%$661.16M$170.28M0.00709Short Interest ↓Analyst RevisionRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$803.44M$25.55M0.00304Gap DownHigh Trading VolumeARQTArcutis Biotherapeutics1.7417 of 5 stars$10.18+0.9%$15.50+52.3%+391.8%$1.18B$59.61M0.00150ANIPANI Pharmaceuticals4.3361 of 5 stars$55.10-1.1%$77.33+40.4%+7.4%$1.17B$486.82M0.00642Positive NewsARDXArdelyx4.0013 of 5 stars$4.92+2.7%$10.42+111.7%+12.3%$1.13B$124.46M0.00267Short Interest ↑BCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.05BN/A0.0032Analyst RevisionAPLTApplied Therapeutics4.3431 of 5 stars$9.43+5.6%$12.50+32.6%+373.9%$1.04B$9.99M0.0030AVDLAvadel Pharmaceuticals2.3476 of 5 stars$10.75+0.3%$24.43+127.2%-7.5%$1.03B$27.96M0.00154Short Interest ↓ZYMEZymeworks2.4008 of 5 stars$14.55-1.5%$19.00+30.6%+74.0%$1.02B$76.01M0.00290 Related Companies and Tools Related Companies FATE Competitors ADPT Competitors RLAY Competitors ARQT Competitors ANIP Competitors ARDX Competitors BCAX Competitors APLT Competitors AVDL Competitors ZYME Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KOD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KOD Stock Alerts